Advertisement

Bone Marrow Failure

  • Sajad KhazalEmail author
  • Jorge Ricardo Galvez Silva
  • Monica Thakar
  • David Margolis
Chapter

Abstract

Bone marrow failure (BMF) syndromes can be classified into inherited and acquired. In addition to the classic clinical presentation of inadequate hematopoiesis (anemia, leukopenia, and thrombocytopenia), which can initially be isolated cytopenias and then progress to marrow aplasia, inherited bone marrow failure syndromes can present with characteristic non-hematologic clinical findings. Patients can be diagnosed shortly after birth or the diagnosis can be delayed into adulthood. BMF syndromes can be premalignant conditions that can progress into myelodysplastic syndrome and/or acute leukemia. Some patients are at higher risk of solid tumors. Early diagnosis, prompt management of complications (infections, bleeding, organ failures), and early referral for hematopoietic stem cell transplantation can be associated with improved outcome. In this chapter we will discuss the most common bone marrow failure syndromes, acquired idiopathic aplastic anemia, Fanconi anemia, Diamond-Blackfan anemia, dyskeratosis congenita, and Shwachman-Bodian-Diamond syndrome.

Keywords

Bone marrow failure Aplastic anemia Fanconi anemia Dyskeratosis congenita Diamond-Blackfan anemia Shwachman-Bodian-Diamond syndrome 

References

  1. 1.
    Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–23.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Howard SC, Naidu PE, Hu XJ, et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer. 2004;43(5):545–51.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45(3):355–63.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177–82.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Khatib Z, Wilimas J, Wang W. Outcome of moderate aplastic anemia in children. Am J Pediatr Hematol Oncol. 1994;16(1):80–5.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. Pediatr Clin N Am. 2013;60(6):1311–36.CrossRefGoogle Scholar
  7. 7.
    Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15(3):162–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Knospe WH, Crosby WH. Aplastic anaemia: a disorder of the bone-marrow sinusoidal microcirculation rather than stem-cell failure? Lancet. 1971;1(7688):20–2.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11–8.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Sutherland DR, Kuek N, Davidson J, et al. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom. 2007;72(3):167–77.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726–35.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117(17):4434–41.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore). 1992;71(1):24–43.CrossRefGoogle Scholar
  16. 16.
    Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013;48(2):168–73.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90(3):1009–13.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Jeng MR, Naidu PE, Rieman MD, et al. Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer. 2005;45(2):170–5.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009;94(12):1661–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73(2):606–13.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 2010;99(1):1–15.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion. 2004;44(6):814–25.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–50.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Welte M. Erythrocyte transfusion: update of the guidelines “therapy with blood components and plasma derivatives”. Anaesthesist. 2009;58(11):1150–8.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Marsh J, Socie G, Tichelli A, et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol. 2010;150(3):377–9.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101(10):4195–200.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19(3):181–99.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA. Antithymocyte globulin hypersensitivity in bone marrow failure patients. JAMA. 1988;260(21):3164–7.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784–91.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69–80.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–36.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339–46.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Pagliuca S, Peffault de Latour R, Volt F, et al. Long-term outcomes of cord blood transplantation from an HLA-identical sibling for patients with bone marrow failure syndromes: a report from eurocord, cord blood committee and severe aplastic anemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1939–48.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054–9.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Cheng Y, Xu Z, Zhang Y, et al. First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy. Clin Transpl. 2017 PMID: 29297952Google Scholar
  38. 38.
    Fanconi G. Familiaere infantile pernizisaartige anaemie. Jahrbuch Kinderheild. 1927;117:257–80.Google Scholar
  39. 39.
    Triemstra J, Rhodes L, Waggoner DJ, Onel K. A review of Fanconi anemia for the practicing pediatrician. Pediatr Ann. 2015;44(10):444–5, 448, 450, 452PubMedCrossRefGoogle Scholar
  40. 40.
    Soulier J, Leblanc T, Larghero J, et al. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood. 2005;105(3):1329–36.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98(5):2532–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Fargo JH, Rochowski A, Giri N, Savage SA, Olson SB, Alter BP. Comparison of chromosome breakage in non-mosaic and mosaic patients with Fanconi anemia, relatives, and patients with other inherited bone marrow failure syndromes. Cytogenet Genome Res. 2014;144(1):15–27.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249–56.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood. 2016;127(24):2971–9.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Diamond LK, Blackfan KD. Hypoplastic anemia. Am J Dis Child. 1938;56:464.Google Scholar
  46. 46.
    Diamond LK, Allen DM, Magill FB. Congenital (erythroid) hypoplastic anemia. A 25-year study. Am J Dis Child. 1961;102:403–15.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116(19):3715–23.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    West AH, Churpek JE. Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program. 2017;2017(1):79–87.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859–76.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Wilson DB, Link DC, Mason PJ, Bessler M. Inherited bone marrow failure syndromes in adolescents and young adults. Ann Med. 2014;46(6):353–63.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Clinton C, Gazda HT. Diamond-Blackfan Anemia. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews((R)). Seattle: University of Washington; 1993.Google Scholar
  52. 52.
    Fargo JH, Kratz CP, Giri N, et al. Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia. Br J Haematol. 2013;160(4):547–54.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115(16):3196–205.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40(8):963–70.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Fumagalli S, Di Cara A, Neb-Gulati A, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol. 2009;11(4):501–8.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117(9):2567–76.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Keel SB, Doty RT, Yang Z, et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. Science. 2008;319(5864):825–8.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46(5):558–64.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Calado RT, Cle DV. Treatment of inherited bone marrow failure syndromes beyond transplantation. Hematology Am Soc Hematol Educ Program. 2017;2017(1):96–101.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Vlachos A, Rosenberg PS, Kang J, Atsidaftos E, Alter BP, Lipton JM. Myelodysplastic syndrome and gastrointestinal carcinomas characterize the cancer risk in Diamond Blackfan anemia: a report from the Diamond Blackfan anemia registry. Blood. 2016;128(122):333.Google Scholar
  61. 61.
    Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815–9.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Hematology Am Soc Hematol Educ Program. 2017;2017(1):88–95.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet Med. 2010;12(12):753–64.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110(4):768–79.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480–6.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Parry EM, Alder JK, Qi X, Chen JJ, Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607–11.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006;107(7):2680–5.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Savage SA, Alter BP. The role of telomere biology in bone marrow failure and other disorders. Mech Ageing Dev. 2008;129(1–2):35–47.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Baerlocher GM, Lansdorp PM. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A. 2003;55(1):1–6.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110(5):1439–47.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2012;97(3):353–9.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165(3):349–57.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Townsley DM, Dumitriu B, Young NS. Danazol treatment for telomere diseases. N Engl J Med. 2016;375(11):1095–6.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Al-Rahawan MM, Giri N, Alter BP. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int J Hematol. 2006;83(3):275–6.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Dietz AC, Orchard PJ, Baker KS, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011;46(1):98–104.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Gadalla SM, Sales-Bonfim C, Carreras J, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238–43.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Bodian M, Sheldon W, Lightwood R. Congenital hypoplasia of the exocrine pancreas. Acta Paediatr. 1964;53:282–93.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Shwachman H, Diamond LK, Oski FA, Khaw KT. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr. 1964;65:645–63.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Goobie S, Popovic M, Morrison J, et al. Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum Genet. 2001;68(4):1048–54.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003;33(1):97–101.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Toiviainen-Salo S, Raade M, Durie PR, et al. Magnetic resonance imaging findings of the pancreas in patients with Shwachman-Diamond syndrome and mutations in the SBDS gene. J Pediatr. 2008;152(3):434–6.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90(1):45–53.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Savilahti E, Rapola J. Frequent myocardial lesions in Shwachman's syndrome. Eight fatal cases among 16 Finnish patients. Acta Paediatr Scand. 1984;73(5):642–51.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am. 2009;23(2):233–48.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y Acad Sci. 2011;1242:40–55.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing 2019

Authors and Affiliations

  • Sajad Khazal
    • 1
    Email author
  • Jorge Ricardo Galvez Silva
    • 2
  • Monica Thakar
    • 3
  • David Margolis
    • 3
  1. 1.The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Nicklaus Children’s HospitalMiami Children’s Health SystemMiamiUSA
  3. 3.Children’s Hospital of WisconsinMilwaukeeUSA

Personalised recommendations